

Slovenia

Population 2016

2.1 million

Estimates of TB burden*, 2016	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.013 (0.013–0.013)	0.61 (0.61–0.62)
Mortality (HIV+TB only)	<0.01 (<0.01–<0.01)	0.01 (0.01–0.01)
Incidence (includes HIV+TB)	0.14 (0.12–0.16)	6.5 (5.6–7.5)
Incidence (HIV+TB only)	<0.01 (<0.01–<0.01)	0.05 (0.03–0.08)
Incidence (MDR/RR-TB)**	0 (0–0)	0 (0–0)

Estimated TB incidence by age and sex (thousands)*, 2016			
	0-14 years	> 14 years	Total
Females	<0.01 (<0.01–<0.01)	0.039 (0.033–0.045)	0.045 (0.038–0.052)
Males	<0.01 (<0.01–<0.01)	0.084 (0.072–0.097)	0.091 (0.077–0.1)
Total	0.012 (0.01–0.014)	0.12 (0.1–0.14)	0.14 (0.12–0.16)

TB case notifications, 2016	
Total cases notified	118
Total new and relapse	118
- % tested with rapid diagnostics at time of diagnosis	52%
- % with known HIV status	81%
- % pulmonary	87%
- % bacteriologically confirmed among pulmonary	93%

Universal health coverage and social protection	
TB treatment coverage (notified/estimated incidence), 2016	87% (75–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2016	0.1 (0.08–0.11)

TB/HIV care in new and relapse TB patients, 2016		Number	(%)
Patients with known HIV-status who are HIV-positive			
- on antiretroviral therapy	1	100%	

Drug-resistant TB care, 2016			
	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			0 (0–0)
Estimated % of TB cases with MDR/RR-TB	0% (0–3.9)	0% (0–71)	
% notified tested for rifampicin resistance	93%	80%	109
MDR/RR-TB cases tested for resistance to second-line drugs			0
Laboratory-confirmed cases		MDR/RR-TB: 0, XDR-TB: 0	
Patients started on treatment ****		MDR/RR-TB: 0, XDR-TB: 0	

Treatment success rate and cohort size		
	Success	Cohort
New and relapse cases registered in 2015	81%	129
Previously treated cases, excluding relapse, registered in 2015	100%	1
HIV-positive TB cases registered in 2015		0
MDR/RR-TB cases started on second-line treatment in 2014		
XDR-TB cases started on second-line treatment in 2014		

TB preventive treatment, 2016	
% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	100% (100–100)

TB financing, 2017	
National TB budget (US\$ millions)	

* Ranges represent uncertainty intervals


** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history

**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)



— Incidence
— Notified (new and relapse)
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2016



■ Females ■ Males

Treatment success rate (%)



— New and relapse
— Retreatment, excluding relapse
— HIV-positive — MDR/RR-TB — XDR-TB